Recent advances and opportunities for improving diagnosis of amyotrophic lateral sclerosis

References

• Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1998 Oct;160(Suppl 1):S6–24.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. Philadelphia: F.A. Davis; 1998.
   Google Scholar
• Lambert EH, Mulder DW. Electromyographic studies in amyotrophic lateral sclerosis. Proc Staff Meet Mayo Clin. 1957 Aug 21;32(17):441–446.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci. 1994 Jul;124(Suppl):96–107.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorder. 2000 Dec;1(5):293–299.
   PubMed Web of Science ®Google Scholar
• De Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiology. 2008 Mar;119(3):497–503.
   PubMed Web of Science ®Google Scholar
• Jang JS, Bae JS. AWAJI criteria are not always superior to the previous criteria: a meta-analysis. Muscle Nerve. 2015 Jun;51(6):822–829.
   PubMed Web of Science ®Google Scholar
• Okita T, Nodera H, Shibuta Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci. 2011 Mar 15;302(1–2):29–32.
   PubMed Web of Science ®Google Scholar
• Schrooten M, Smetcoren C, Robberecht W, et al. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011 Jul;70(1):79–83.
   PubMed Web of Science ®Google Scholar
• Boekestein WA, Kleine BU, Hageman G, et al. Sensitivity and specificity of the ‘Awaji’ electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler. 2010 Dec;11(6):497–501.
   PubMed Web of Science ®Google Scholar
• Chen A, Weimer L, Brannagan T 3rd, et al. Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve. 2010 Nov;42(5):831–832.
   PubMed Web of Science ®Google Scholar
• Douglass CP, Kandler RH, Shaw PJ, et al. An evaluation of neurophysiological criteria used in the diagnosis of motor neuron disease. J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):646–649.
   PubMed Web of Science ®Google Scholar
• Costa J, Swash M, De Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012 Nov;69(11):1410–1416.
   PubMedGoogle Scholar
• Geevasinga N, Loy CT, Menon P, et al. Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data. Clin Neurophysiology. 2016 Apr 16;127(7):2684–2691.
   Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria – 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5–6):291–292.
   PubMed Web of Science ®Google Scholar
• Kaji R, Kuzuhara S, Iwasaki Y, et al. Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS by more if treated early: randomized double-blind, phase 3 clinical trial. Abstract at the 26th International MND/ALS Symposium, Orlando, FL, 2015.
   Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5–6):406–413.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7–8):610–617.
   PubMed Web of Science ®Google Scholar
• Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015 Nov;33(4):807–830.
   PubMed Web of Science ®Google Scholar
• Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015 Mar 27;347(6229):1436–1441.
   PubMed Web of Science ®Google Scholar
• Keller MF, Ferrucci L, Singleton AB, et al. Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2014 Sep;71(9):1123–1134.
   PubMed Web of Science ®Google Scholar
• Chervyakov AV, Bakulin IS, Savitskaya NG, et al. Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve. 2015 Jan;51(1):125–131.
   PubMed Web of Science ®Google Scholar
• Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015 May;14(5):478–484.
   Web of Science ®Google Scholar
• Vucic S, Ziemann U, Eisen A, et al. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1161–1170.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Pullman SL, Shungu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology. 2004 May 25;62(10):1753–1757.
   PubMed Web of Science ®Google Scholar
• Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology. 2009 Feb 10;72(6):498–504.
   PubMed Web of Science ®Google Scholar
• Gooch CL, Doherty TJ, Chan KM, et al. Motor unit number estimation: a technology and literature review. Muscle Nerve. 2014 Dec;50(6):884–893.
   PubMed Web of Science ®Google Scholar
• Gooch CL, Pullman SL, Shungu DC, et al. Motor unit number estimation (MUNE) in diseases of the motor neuron: utility and comparative analysis in a multimodal biomarker study. Suppl Clin Neurophysiol. 2009;60:153–162.
   PubMedGoogle Scholar
• Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011 Jul 19;77(3):235–241.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007 Apr 24;68(17):1402–1410.
   PubMed Web of Science ®Google Scholar
• Nandedkar SD, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010 Nov;42(5):798–807.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Barkhaus PE, Burkhardt C, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1172–1179.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Nandedkar S, Stalberg E, et al. Motor Unit Number Index (MUNIX): a novel neurophysiological marker for neuromuscular disorders; test-retest reliability in healthy volunteers. Clin Neurophysiology. 2011 Sep;122(9):1867–1872.
   PubMed Web of Science ®Google Scholar
• Fathi D, Mohammadi B, Dengler R, et al. Lower motor neuron involvement in ALS assessed by motor unit number index (MUNIX): long-term changes and reproducibility. Clin Neurophysiology. 2016 Apr;127(4):1984–1988.
   PubMed Web of Science ®Google Scholar
• Nandedkar SD, Barkhaus PE, Stalberg EV. Reproducibility of MUNIX in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2011 Dec;44(6):919–922.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014 Mar;49(3):441–443.
   PubMed Web of Science ®Google Scholar
• Turner MR, Verstraete E. What does imaging reveal about the pathology of amyotrophic lateral sclerosis? Curr Neurol Neurosci Rep. 2015 Jul;15(7):45.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Foerster BR. Neuroimaging as a new diagnostic modality in amyotrophic lateral sclerosis. Neurotherapeutics. 2015 Apr;12(2):403–416.
   PubMed Web of Science ®Google Scholar
• Chio A, Pagani M, Agosta F, et al. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurology. 2014 Dec;13(12):1228–1240.
   PubMed Web of Science ®Google Scholar
• Cosottini M, Donatelli G, Costagli M, et al. High-resolution 7T MR imaging of the motor cortex in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 2015 Dec 17;37(3):455–461.
   Web of Science ®Google Scholar
• Bede P, Bokde A, Elamin M, et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):766–773.
   PubMed Web of Science ®Google Scholar
• Menke RA, Korner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. 2014 Sep;137(Pt 9):2546–2555.
   PubMed Web of Science ®Google Scholar
• Lillo P, Mioshi E, Burrell JR, et al. Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One. 2012;7(8):e43993.
   PubMed Web of Science ®Google Scholar
• Rajagopalan V, Pioro EP. Distinct patterns of cortical atrophy in ALS patients with or without dementia: an MRI VBM study. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3–4):216–225.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):383–388.
   PubMed Web of Science ®Google Scholar
• Schuster C, Kasper E, Machts J, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol. 2013 Nov;260(11):2856–2864.
   PubMed Web of Science ®Google Scholar
• Walhout R, Westeneng HJ, Verstraete E, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):288–294.
   PubMed Web of Science ®Google Scholar
• Tang M, Chen X, Zhou Q, et al. Quantitative assessment of amyotrophic lateral sclerosis with diffusion tensor imaging in 3.0T magnetic resonance. Int J Clin Exp Med. 2015;8(5):8295–8303.
   PubMed Web of Science ®Google Scholar
• van der Graaff MM, Sage CA, Caan MW, et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain. 2011 Apr;134(Pt 4):1211–1228.
   PubMed Web of Science ®Google Scholar
• Menke RA, Abraham I, Thiel CS, et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol. 2012 Nov;69(11):1493–1499.
   PubMedGoogle Scholar
• Trojsi F, Corbo D, Caiazzo G, et al. Motor and extramotor neurodegeneration in amyotrophic lateral sclerosis: a 3T high angular resolution diffusion imaging (HARDI) study. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7–8):553–561.
   PubMed Web of Science ®Google Scholar
• Kassubek J, Muller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. 2014 Jun;137(Pt 6):1733–1740.
   PubMed Web of Science ®Google Scholar
• Steinbach R, Loewe K, Kaufmann J, et al. Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography. J Neurol. 2015 Oct;262(10):2257–2270.
   PubMed Web of Science ®Google Scholar
• Kim JE, Oh JS, Sung JJ, et al. Diffusion tensor tractography analysis of the corpus callosum fibers in amyotrophic lateral sclerosis. J Clin Neurol. 2014 Jul;10(3):249–256.
   PubMed Web of Science ®Google Scholar
• Agosta F, Pagani E, Petrolini M, et al. Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. AJNR Am J Neuroradiol. 2010 Sep;31(8):1457–1461.
   PubMed Web of Science ®Google Scholar
• Schweitzer AD, Liu T, Gupta A, et al. Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis. AJR Am J Roentgenol. 2015 May;204(5):1086–1092.
   PubMed Web of Science ®Google Scholar
• Foerster BR, Carlos RC, Dwamena BA, et al. Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis. Annals Clinical Translational Neurology. 2014 Feb;1(2):107–114.
   PubMed Web of Science ®Google Scholar
• Canosa A, Pagani M, Cistaro A, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016 Jan 5;86(1):44–49.
   PubMed Web of Science ®Google Scholar
• Kew JJ, Goldstein LH, Leigh PN, et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain. 1993 Dec;116(Pt 6):1399–1423.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Langen KJ, Regard M, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992 Feb;85(2):81–89.
   PubMed Web of Science ®Google Scholar
• Pagani M, Chio A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014 Sep 16;83(12):1067–1074.
   PubMed Web of Science ®Google Scholar
• Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014 May;71(5):553–561.
   PubMed Web of Science ®Google Scholar
• Cistaro A, Cuccurullo V, Quartuccio N, et al. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:237437.
   PubMed Web of Science ®Google Scholar
• Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):467–472.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016 Jan;79(1):152–158.
   PubMed Web of Science ®Google Scholar
• Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015 May;86(5):565–573.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015 Jun 2;84(22):2247–2257.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2015 Jan;22(1):215–218.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Jardel C, Salachas F, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degener. 2016;17(5–6):404–413.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006 Mar 28;66(6):852–856.
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091.
   PubMed Web of Science ®Google Scholar
• Reijn TS, Abdo WF, Schelhaas HJ, et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009 Apr;256(4):615–619.
   PubMed Web of Science ®Google Scholar
• Lehnert S, Costa J, de Carvalho M, et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5–6):344–350.
   PubMed Web of Science ®Google Scholar
• Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014 Apr;71(4):442–448.
   PubMed Web of Science ®Google Scholar
• Wilke C, Deuschle C, Rattay TW, et al. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015 Feb;36(2):1072–1074.
   PubMed Web of Science ®Google Scholar
• Takahashi I, Hama Y, Matsushima M, et al. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol Brain. 2015;8(1):67.
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Muller K, Zondler L, et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014 Nov;137(Pt 11):2938–2950.
   PubMed Web of Science ®Google Scholar
• Yang X, Gao L, Wu X, et al. Increased levels of MIP-1alpha in CSF and serum of ALS. Acta Neurol Scand. 2015 Oct;134(2):94–100.
   Web of Science ®Google Scholar
• Liu J, Gao L, Zang D. Elevated levels of IFN-gamma in CSF and serum of patients with amyotrophic lateral sclerosis. PLoS One. 2015;10(9):e0136937.
   Google Scholar
• Pagliardini V, Pagliardini S, Corrado L, et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci. 2015 Jan 15;348(1–2):245–250.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Sharma A, Mishra P, et al. Chitotriosidase – a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics. 2013;10(1):19.
   PubMed Web of Science ®Google Scholar
• Kirk K, Gennings C, Hupf JC, et al. Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients. Ann Neurol. 2014 Oct;76(4):620–624.
   PubMed Web of Science ®Google Scholar
• Fang L, Huber-Abel F, Teuchert M, et al. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2009 Oct 15;285(1–2):62–66.
   PubMed Web of Science ®Google Scholar
• Niebroj-Dobosz I, Janik P, Sokolowska B, et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2010 Feb;17(2):226–231.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Steinacker P, Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5–6):351–356.
   PubMed Web of Science ®Google Scholar
• Noto Y, Shibuya K, Sato Y, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011 Mar;12(2):140–143.
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology. 2006 Apr 25;66(8):1218–1222.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5–6):362–370.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhou S, Cai H, et al. VEGF levels in CSF and serum in mild ALS patients. J Neurol Sci. 2014 Nov 15;346(1–2):216–220.
   PubMed Web of Science ®Google Scholar
• Pronto-Laborinho AC, Pinto S, de Carvalho M. Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:947513.
   PubMed Web of Science ®Google Scholar
• Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999 Apr 22;52(7):1311–1323.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorder. 2005 Sep;6(3):145–154.
   PubMed Web of Science ®Google Scholar
• Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology. 2013 Mar;12(3):310–322.
   PubMed Web of Science ®Google Scholar